Related references
Note: Only part of the references are listed.Phase II Trial of Neoadjuvant Carboplatin and Nab-Paclitaxel in Patients with Triple-Negative Breast Cancer
Yuan Yuan et al.
ONCOLOGIST (2021)
Metabolic-Pathway-Based Subtyping of Triple-Negative Breast Cancer Reveals Potential Therapeutic Targets
Yue Gong et al.
CELL METABOLISM (2021)
Adjuvant addition of capecitabine to early-stage triple-negative breast cancer patients receiving standard chemotherapy: a meta-analysis
Yan Li et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Long-term survival analysis of addition of carboplatin to neoadjuvant chemotherapy in HER2-negative breast cancer
Madoka Iwase et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Pathologic Complete Response after Neoadjuvant Chemotherapy and Impact on Breast Cancer Recurrence and Survival: A Comprehensive Meta-analysis
Laura M. Spring et al.
CLINICAL CANCER RESEARCH (2020)
Carboplatin plus taxanes are non-inferior to epirubicin plus cyclophosphamide followed by taxanes as adjuvant chemotherapy for early triple-negative breast cancer
Feng Du et al.
BREAST CANCER RESEARCH AND TREATMENT (2020)
Molecular subtypes and precision treatment of triple-negative breast cancer
Shen Zhao et al.
ANNALS OF TRANSLATIONAL MEDICINE (2020)
Platinum-based chemotherapy in advanced triple-negative breast cancer: A multicenter real-world study in China
Yimeng Chen et al.
INTERNATIONAL JOURNAL OF CANCER (2020)
Effect of Adjuvant Paclitaxel and Carboplatin on Survival in Women With Triple-Negative Breast Cancer A Phase 3 Randomized Clinical Trial
Ke-Da Yu et al.
JAMA ONCOLOGY (2020)
Most neoadjuvant chemotherapy for triple-negative breast cancer should include platinum
Rebecca Dent et al.
LANCET ONCOLOGY (2020)
Triple-negative breast cancer molecular subtyping and treatment progress
Li Yin et al.
BREAST CANCER RESEARCH (2020)
Efficacy of platinum in advanced triple-negative breast cancer with germline BRCA mutation determined by next generation sequencing
Nan Wang et al.
CHINESE JOURNAL OF CANCER RESEARCH (2020)
Genomic and Transcriptomic Landscape of Triple-Negative Breast Cancers: Subtypes and Treatment Strategies
Yi-Zhou Jiang et al.
CANCER CELL (2019)
Recent advances in triple negative breast cancer: the immunotherapy era
Antonio Marra et al.
BMC MEDICINE (2019)
Weekly carboplatin plus neoadjuvant anthracycline-taxane-based regimen in early triple-negative breast cancer: a prospective phase II trial by the Breast Cancer Task Force of the Belgian Society of Medical Oncology (BSMO)
Christel Fontaine et al.
BREAST CANCER RESEARCH AND TREATMENT (2019)
Systemic treatment of patients with early breast cancer: recent updates and state of the art
Rafael Caparica et al.
BREAST (2019)
The effect of neoadjuvant platinum-based chemotherapy in BRCA mutated triple negative breast cancers -systematic review and meta-analysis
Olga Caramelo et al.
HEREDITARY CANCER IN CLINICAL PRACTICE (2019)
Platinum-based neoadjuvant chemotherapy in triple-negative breast cancer: a systematic review and meta-analysis
F. Poggio et al.
ANNALS OF ONCOLOGY (2018)
Update on the Treatment of Early-Stage Triple-Negative Breast Cancer
Priyanka Sharma
CURRENT TREATMENT OPTIONS IN ONCOLOGY (2018)
Addition of the PARP inhibitor veliparib plus carboplatin or carboplatin alone to standard neoadjuvant chemotherapy in triple-negative breast cancer (BrighTNess): a randomised, phase 3 trial
Sibylle Loibl et al.
LANCET ONCOLOGY (2018)
Survival analysis of carboplatin added to an anthracycline/taxane-based neoadjuvant chemotherapy and HRD score as predictor of response-final results from GeparSixto
S. Loibl et al.
ANNALS OF ONCOLOGY (2018)
Ten-year results of intense dose-dense chemotherapy show superior survival compared with a conventional schedule in high-risk primary breast cancer: final results of AGO phase III iddEPC trial
V. Moebus et al.
ANNALS OF ONCOLOGY (2018)
Efficacy of adjuvant chemotherapy with carboplatin for early triple negative breast cancer: a single center experience
Marcus Vetter et al.
ONCOTARGET (2017)
Triple-negative breast cancer: challenges and opportunities of a heterogeneous disease
Giampaolo Bianchini et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
Better pathologic complete response and relapse-free survival after carboplatin plus paclitaxel compared with epirubicin plus paclitaxel as neoadjuvant chemotherapy for locally advanced triple-negative breast cancer: a randomized phase 2 trial
Pin Zhang et al.
ONCOTARGET (2016)
Assessing the Role of Platinum Agents in Aggressive Breast Cancers
William M. Sikov
CURRENT ONCOLOGY REPORTS (2015)
Randomized phase II study of weekly paclitaxel with and without carboplatin followed by cyclophosphamide/epirubicin/5-fluorouracil as neoadjuvant chemotherapy for stage II/IIIA breast cancer without HER2 overexpression
Masashi Ando et al.
BREAST CANCER RESEARCH AND TREATMENT (2014)
A randomized phase II trial of platinum salts in basal-like breast cancer patients in the neoadjuvant setting. Results from the GEICAM/2006-03, multicenter study
E. Alba et al.
BREAST CANCER RESEARCH AND TREATMENT (2012)
Dose-Dense Chemotherapy in Nonmetastatic Breast Cancer: A Systematic Review and Meta-analysis of Randomized Controlled Trials
Luisa Bonilla et al.
JNCI-JOURNAL OF THE NATIONAL CANCER INSTITUTE (2010)
Share Paper
